Subscribe
shutterstock_2162525475_jonathan-weiss
shutterstock_2162525475_jonathan-weiss
4 October 2022Big PharmaStaff writer

SCOTUS invites govt comment on Teva clash

The US Supreme Court has asked the US government to weigh in on whether the court should hear the ‘skinny-label’ dispute between Teva and GSK.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More on this story

Americas
Teva takes long-running ‘skinny label’ suit to SCOTUS
14 July 2022   Generics giant’s petition cites the cost of medicine and first-principles of innovation.
Big Pharma
GSK presses court to deny Teva’s ‘skinny label’ petition
25 August 2022   Teva’s petition relies on a “blatantly misleading” question, argues GSK | Case presents “no new issues” that haven’t already been decided.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility